First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study

被引：0
|
作者：
Djelila Allouache
Sulochana R Gawande
Michele Tubiana-Hulin
Nicole Tubiana-Mathieu
Sophie Piperno-Neumann
Fawzia Mefti
Laurence Bozec
Jean-Yves Genot
机构：
[1] Lion sur mer,Centre F. Baclesse
[2] Lilly Corporate,Eli Lilly and Company
[3] Ctr René Huguenin,undefined
[4] Hopital Dupuytren,undefined
[5] Hospital Curie,undefined
[6] Lilly France,undefined
来源：
BMC Cancer | / 5卷
关键词：
Paclitaxel; Gemcitabine; Metastatic Breast Cancer; Anthracyclines; Inflammatory Breast Cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer
    Brufsky, Adam
    Hoelzer, Karen
    Beck, Thaddeus
    Whorf, Robert
    Keaton, Mark
    Nadella, Padma
    Krill-Jackson, Elisa
    Kroener, Joan
    Middleman, Edward
    Frontiera, Michael
    Paul, Devchand
    Panella, Timothy
    Bromund, Jane
    Zhao, Luping
    Orlando, Mauro
    Tai, Fritz
    Marciniak, Martin D.
    Obasaju, Coleman
    Hainsworth, John
    CLINICAL BREAST CANCER, 2011, 11 (04) : 211 - 220
  • [2] Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial
    Blackstein, M
    Vogel, CL
    Ambinder, R
    Cowan, J
    Iglesias, J
    Melemed, A
    ONCOLOGY, 2002, 62 (01) : 2 - 8
  • [3] Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience
    Alessandro Passardi
    Ilaria Massa
    Wainer Zoli
    Lorenzo Gianni
    Carlo Milandri
    Federica Zumaglini
    Oriana Nanni
    Roberta Maltoni
    Giovanni Luca Frassineti
    Dino Amadori
    BMC Cancer, 6
  • [4] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    J. Salvador
    L. Manso
    J. de la Haba
    A. Jaen
    E. Ciruelos
    M. C. de Villena
    M. Gil
    A. Murias
    A. Galan
    C. Jara
    J. Bayo
    J. M. Baena
    J. Casal
    J. R. Mel
    I. Blancas
    P. Sanchez Rvira
    Clinical and Translational Oncology, 2015, 17 : 160 - 166
  • [5] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Salvador, J.
    Manso, L.
    de la Haba, J.
    Jaen, A.
    Ciruelos, E.
    de Villena, M. C.
    Gil, M.
    Murias, A.
    Galan, A.
    Jara, C.
    Bayo, J.
    Baena, J. M.
    Casal, J.
    Mel, J. R.
    Blancas, I.
    Sanchez Rvira, P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (02) : 160 - 166
  • [6] Combination versus sequential paclitaxel plus gemcitabine as first-line chemotherapy for women with metastatic breast cancer: a prospective randomized phase II study
    Shao, Bin
    Song, Guohong
    Li, Huiping
    Di, Lijun
    Jiang, Hanfang
    Liang, Xu
    Yan, Ying
    Zhang, Ruyan
    Ran, Ran
    Wang, Jing
    Liu, Xiaoran
    You, Miaoning
    JOURNAL OF BUON, 2018, 23 (06): : 1583 - 1590
  • [7] A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
    Fukahori, Masaru
    Miwa, Keisuke
    Murotani, Kenta
    Naito, Yoshiki
    Ushijima, Tomoyuki
    Sakaue, Takahiko
    Tanaka, Toshimitsu
    Nagasu, Sachiko
    Suga, Hideya
    Kakuma, Tatsuyuki
    Okabe, Yoshinobu
    Torimura, Takuji
    MEDICINE, 2021, 100 (20) : E26052
  • [8] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
    F Cappuzzo
    F Mazzoni
    A Gennari
    S Donati
    B Salvadori
    C Orlandini
    G L Cetto
    A Molino
    E Galligioni
    M Mansutti
    S Tumolo
    A Lucentini
    F Valduga
    S Bartolini
    L Crinò
    P F Conte
    British Journal of Cancer, 2004, 90 : 31 - 35
  • [9] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
    Cappuzzo, F
    Mazzoni, F
    Gennari, A
    Donati, S
    Salvadori, B
    Orlandini, C
    Cetto, GL
    Molino, A
    Galligioni, E
    Mansutti, M
    Tumolo, S
    Lucentini, A
    Valduga, F
    Bartolini, S
    Crinò, L
    Conte, PF
    BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 31 - 35
  • [10] Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
    Possinger, K
    Kaufmann, M
    Coleman, R
    Stuart, NSA
    Helsing, M
    Ohnmacht, U
    Arning, M
    ANTI-CANCER DRUGS, 1999, 10 (02) : 155 - 162
12345